Chemomab Therapeutics Files Form 6-K
Ticker: CMMB · Form: 6-K · Filed: Aug 21, 2024 · CIK: 1534248
| Field | Detail |
|---|---|
| Company | Chemomab Therapeutics LTD. (CMMB) |
| Form Type | 6-K |
| Filed Date | Aug 21, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer, sec-filing
TL;DR
Chemomab Therapeutics (CMMB) filed a 6-K on Aug 21, 2024, updating its status as a foreign private issuer.
AI Summary
Chemomab Therapeutics Ltd. filed a Form 6-K on August 21, 2024, reporting on its activities for the month of August 2024. The company, formerly known as Anchiano Therapeutics Ltd. and BioCancell Ltd., is incorporated in Israel and operates in the pharmaceutical preparations sector. This filing is made pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Why It Matters
This filing provides an update on Chemomab Therapeutics' regulatory reporting, indicating ongoing operations and compliance for investors and stakeholders.
Risk Assessment
Risk Level: low — This is a routine regulatory filing by a foreign private issuer and does not contain new financial or operational information that would inherently increase risk.
Key Numbers
- 001-38807 — SEC File Number (Identifies the company's filing with the SEC.)
Key Players & Entities
- Chemomab Therapeutics Ltd. (company) — Registrant
- Anchiano Therapeutics Ltd. (company) — Former company name
- BioCancell Ltd. (company) — Former company name
- 001-38807 (dollar_amount) — SEC File Number
- 20240821 (date) — Filing date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information that the registrant has made or is required to make public in its home country.
When was Chemomab Therapeutics Ltd. formerly known as Anchiano Therapeutics Ltd.?
The date of the name change from Anchiano Therapeutics Ltd. to Chemomab Therapeutics Ltd. was September 6, 2018.
What is Chemomab Therapeutics Ltd.'s fiscal year end?
Chemomab Therapeutics Ltd.'s fiscal year ends on December 31.
What is the SIC code for Chemomab Therapeutics Ltd.?
The Standard Industrial Classification (SIC) code for Chemomab Therapeutics Ltd. is 2834, which corresponds to Pharmaceutical Preparations.
What is the principal executive office address for Chemomab Therapeutics Ltd.?
The principal executive offices are located at Kiryat Atidim, Building 7, Tel-Aviv, Israel.
Filing Stats: 425 words · 2 min read · ~1 pages · Grade level 13 · Accepted 2024-08-21 07:00:21
Filing Documents
- zk2431846.htm (6-K) — 21KB
- exhibit_99-1.htm (EX-99.1) — 459KB
- exhibit_99-2.htm (EX-99.2) — 153KB
- exhibit_99-3.htm (EX-99.3) — 156KB
- 0001178913-24-002717.txt ( ) — 2097KB
- cmmb-20240630.xsd (EX-101.SCH) — 21KB
- cmmb-20240630_cal.xml (EX-101.CAL) — 24KB
- cmmb-20240630_def.xml (EX-101.DEF) — 44KB
- cmmb-20240630_lab.xml (EX-101.LAB) — 214KB
- cmmb-20240630_pre.xml (EX-101.PRE) — 88KB
- zk2431846_htm.xml (XML) — 97KB
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 99.3 Press Release dated August 21, 2024 titled "Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Corporate Update" 101 Interactive data files pursuant to Rule 405 of Regulation S-T: (i) Unaudited Interim Consolidated Balance Sheets, (ii) Unaudited Interim Consolidated Statements of Operations, (iii) Unaudited Interim Consolidated Statements of Comprehensive Loss, (iv) Unaudited Consolidated Statements of Redeemable Convertible Preferred Shares and Changes in Shareholders' Equity (v) Unaudited Consolidated Statements of Cash Flows and (vi) related notes to these consolidated financial statements. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CHEMOMAB THERAPEUTICS LTD. Date: August 21, 2024 By: /s/ Sigal Fattal Sigal Fattal Chief Financial Officer